BioLamina Launches a Cell Therapy Grade Stem Cell Culture Matrix, Biolaminin 521 CTG, Bridging Discovery and Clinical Cell Therapy

Stockholm (ots/PRNewswire) -

BioLamina (http://www.biolamina.com) (Stockholm) is currently
undergoing an exciting phase entering the growing cell and gene
therapy reagents industry. In order to meet the growing demand for
documentation and traceability required for the manufacture of cells
for therapy, BioLamina has launched a cell therapy grade (CTG)
laminin substrate for clinical use, Biolaminin 521 CTG. "This is a
significant milestone for BioLamina and for cell therapy developers
around the world," says Kristian Tryggvason, CEO of BioLamina.
"Finally there is a highly functional cell therapy grade product
available that for the first time, allowing researchers to take their
early protocols to clinical trials and onwards to commercialized
therapy without significantly changing their manufacturing process."

Since 2009, BioLamina has been providing the stem cell research
community with high quality research reagents that are often crucial
for the potential cell therapy manufacturing process. BioLamina's
best-selling product is human recombinant laminin 521, a cell culture
substrate well documented and scientifically validated in numerous
high-quality journals, such as Cell and Nature. The laminin 521
substrate has solved many manufacturing process-related issues, such
as low cell quality and yield. Over the last decade, laminin 521 has
become a preferred cell culture substrate for both basic researchers
and for researchers and companies with a therapeutic focus, and sales
have increased significantly year after year.

Following the derivation of human embryonic stem cells in 1998 and
with the development of human induced pluripotent stem cells in 2007,
great efforts have been made to create defined culture methods with
high consistency, reproducibility and traceability of the reagents.
This is even more important now as stem cell researchers are
advancing their research projects to clinical studies with cell
therapy candidates. The first CTG substrate, Biolaminin 521 CTG is
now available for researchers and developers, helping the researchers
all the way to enable cell therapy. "The regenerative medicine field
is growing rapidly as more and more companies are entering clinical
trials. It is such a great feeling to see this advancement and
knowing we contribute to it," says Kristian Tryggvason, CEO of
BioLamina.

ABOUT BIOLAMINA AB

BioLamina develops and distributes high quality products for cell
culture based on human recombinant laminins. This technology is based
on research from Dr. Karl Tryggvason's laboratory at the Karolinska
Institutet, Sweden and Duke-NUS, Singapore. By covering surfaces used
for cell culture with recombinant laminins, the cell's natural
environment in the body is mimicked, allowing the cells to thrive and
maintain their function. These substrates help to solve several
issues associated with embryonic stem cell culture as well as other
primary cells, such as low cell growth and quality. With the
introduction of BioLamina's more biologically relevant and defined
matrices, scientists now have more powerful resources to develop
their cultivation systems, enabling clinical development and the
production of new cell therapies.

ots Originaltext: BioLamina AB
Im Internet recherchierbar: http://www.presseportal.de

Contact:
, please contact:
BIOLAMINA AB
Kristian Tryggvason, CEO Telephone +46-70-743-2233
E-mail: communications@biolamina.com

Original-Content von: BioLamina AB, übermittelt durch news aktuell